SCHEMBL900528

SCHEMBL900528

CSc1ccc[c]c1-c1nc2ccccc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.44
RAB9A P51151 8/20 0.44
NPC1 O15118 7/20 0.44
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
L3MBTL1 Q9Y468 5/20 0.44
MAPT P10636 5/20 0.44
GAA P10253 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
TDP1 Q9NUW8 2/20 0.44
ILK Q13418 1/20 0.44
F2RL3 Q96RI0 1/20 0.43
TP53 P04637 2/20 0.42
HSD17B10 Q99714 2/20 0.42
TSHR P16473 1/20 0.42
APP P05067 3/20 0.41
GLA P06280 3/20 0.41
PKM P14618 1/20 0.41
PAX8 Q06710 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5326182 0.81 RAB9A (0.47) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL12474338 0.80 NPC1 (0.40) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL15770980 0.79 KDM4E (0.57) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL31038145 0.77 KDM4E (0.63) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL547335 0.70 NPC1 (0.44) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL713163 0.70 RAB9A (0.50) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL827403 0.70 RAB9A (0.67) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL12474389 0.69 PTGS1 (0.46) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL15226741 0.69 NPC1 (0.50) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2
SCHEMBL7110707 0.69 KDM4E (0.56) KDM4ERAB9ANPC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029357-B2 Benzazole derivatives as histamine H4 receptor ligands BIOPROJET (FR) 2015-05-12 US disclosed
US-20150004181-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands BIOPROJET SOC CIV (FR) 2015-01-01 US disclosed
US-8802664-B2 Benzazole derivatives as histamine H4 receptor ligands BIOPROJECT (FR) 2014-08-12 US disclosed
US-20130231329-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands BIOPROJET (FR) 2013-09-05 US disclosed
EP-2621916-A1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET (FR) 2013-08-07 EP disclosed
WO-2012041860-A1 BENZAZOLE DERIVATIVES AS HISTAMINE H4 RECEPTOR LIGANDS BIOPROJET (FR) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150004181-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands HRH4, HRH3, HRH2 KDM4E 1546/4885RAB9A 2931/4885NPC1 2379/4885
US-20130231329-A1 Benzazole Derivatives as Histamine H4 Receptor Ligands HRH4, HRH3, HRH2 KDM4E 2139/4885RAB9A 2802/4885NPC1 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.